- Home
- BYRN vs GOSS Comparison
BYRN vs GOSS Comparison
Compare BYRN & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BYRN | GOSS |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.0M | 70.8M |
| IPO Year | 2013 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BYRN | GOSS |
|---|---|---|
| Price | $3.87 | $11.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $6.33 | ★ $91.40 |
| AVG Volume (30 Days) | ★ 405.7K | 173.2K |
| Earning Date | 10-08-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $16,566,295.00 | ★ $48,471,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.51 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1692.08 | N/A |
| 52 Week Low | $3.17 | $0.11 |
| 52 Week High | $20.69 | $12.52 |
Technical Indicators
Market Signals| Indicator | BYRN | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 41.71 | 60.87 |
| Support Level | $3.26 | $0.18 |
| Resistance Level | $5.21 | $12.49 |
| Average True Range (ATR) | 0.25 | 1.10 |
| MACD | -0.08 | 0.10 |
| Stochastic Oscillator | 25.20 | 73.92 |
Price Performance
Historical ComparisonAbout BYRN Byrna Technologies Inc.
Byrna Technologies Inc is a designer, manufacturer, retailer, and distributor of technological solutions for security situations that do not require the use of lethal force. The company generates its revenue from the United States, South Africa, Europe, South America, Asia, and Canada.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).